Exclusive Financial Advisor to Altor Bioscience Corporation^* on Second Sale of Preferred Stock

2006—Completed the second sale of Altor BioScience Corporation Preferred Stock to Sanderling, a leading biotech capital investor.  Altor BioScience Corporation develops biopharmaceutical products targeting immunotherapeutic agents for the treatment of cancer, viral infections, inflammatory, and autoimmune diseases and serves customers throughout the United States.

“Altor is very pleased with the results of this financing,” said Dr. Hing Wong, Altor’s Chief Executive Officer”.

*Altor Bioscience Corporation merged with NantCell in 2017 and subsequently went public as ImmunityBio